Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review

Research

BMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j1680 (Published 03 May 2017) Cite this as: BMJ 2017;357:j1680

Data supplement

Web extra

Files in this Data Supplement:

Data Supplement - Appendix: supplementary material

Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study
Process of drug registration in Israel: the correlation between the number of discussions within the Ministry of Health and postapproval variations by EMA and/or FDA
U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018
- Abstract
- Fulltext
- PDF
Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis
- Abstract
- Fulltext
- PDF
New drugs: where did we go wrong and what can we do better?
- Abstract
- Fulltext
- PDF
Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
- Abstract
- Fulltext
- PDF
Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review
- Abstract
- Fulltext
- PDF
New agreement on branded drugs for the NHS
- Abstract
- Fulltext
- PDF
Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
- Abstract
- Fulltext
- PDF
Preapproval and postapproval evidence on drugs for multiple sclerosis
- Abstract
- Fulltext
- PDF